COZADD BRUCE C sold $1.4M of JAZZ
COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $235.12 ($1.41M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The filing updates the record of insider ownership and may slightly influence sentiment, but the pre-arranged 10b5-1 structure generally limits interpretive value for near-term price action.
Market read
A disclosed insider sale datapoint for JAZZ with limited catalyst strength due to 10b5-1 pre-arrangement.
What to watch
10b5-1 plans can be executed regardless of company outlook; without additional context (e.g., multiple concurrent sales, option exercises, or changes in plan parameters), directional inference is weak.
Background
This is an SEC Form 4 insider transaction disclosure (director sale) for Jazz Pharmaceuticals plc.
Ticker impact
Jazz Pharmaceuticals director COZADD BRUCE C sold 6,000 shares for ~$1.41M under a pre-arranged 10b5-1 plan, disclosed via Form 4.
Likely limited near-term impact; any move would be more about broader biotech sentiment than this Form 4.
Form 4 provides a datapoint on ownership change, but the presence of a pre-arranged 10b5-1 plan typically dampens interpretability for trading direction.
Market effects
Minimal; single-company insider transaction with no new clinical/regulatory/commercial catalyst.
None indicated.
None indicated.
Counterpoint
A large dollar amount could still reflect personal liquidity needs, but traders may overreact if they treat 10b5-1 sales as bearish fundamentals.
Key entities
- issuerJazz Pharmaceuticals plc
Subject of the Form 4 insider sale disclosure.
- insiderCOZADD BRUCE C
Director who sold 6,000 shares on 2026-06-01 under a 10b5-1 plan.
